Manipulating Metabolism: Lilly Links With UK Biotech Sitryx
Pair Will Act On Intracellular Metabolic Pathways To Modify Diseases
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
You may also be interested in...
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.